ArticleFrontiers in oncology2021
TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study.
Biao Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
36 papers cite it
this paperpooled itcites it